Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.9%

7 terminated/withdrawn out of 762 trials

Success Rate

96.2%

+9.7% vs industry average

Late-Stage Pipeline

9%

67 trials in Phase 3/4

Results Transparency

3%

6 of 179 completed trials have results

Key Signals

137 recruiting6 with results6 withdrawn

Enrollment Performance

Analytics

N/A
195(39.8%)
Phase 1
118(24.1%)
Phase 2
100(20.4%)
Phase 4
44(9.0%)
Phase 3
23(4.7%)
Early Phase 1
10(2.0%)
490Total
N/A(195)
Phase 1(118)
Phase 2(100)
Phase 4(44)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (762)

Showing 20 of 762 trials
NCT06902740Phase 4Recruiting

PCSK9 Inhibitor With Statin Therapy for Asymptomatic Intracranial Atherosclerosis

Role: collaborator

NCT07643922Not ApplicableNot Yet Recruiting

Endovascular Therapy for Cerebral Vasospasm After Aneurysmal Subarachnoid Hemorrhage

Role: collaborator

NCT07645690Early Phase 1Recruiting

The Safety and Efficacy of Allogeneic CD70 CAR-T Therapy in Unresectable or Metastatic Clear Cell Renal Cell Carcinoma

Role: lead

NCT07635758Phase 1Recruiting

Human Placenta-derived 3D Mesenchymal Stem Cells(Guojianqingke)

Role: lead

NCT07570563Phase 1Recruiting

Clinical Study of the Safety and Efficacy of Allogeneic TCR-enhanced Vδ2 T Cell in Patients With Malignant Tumors.

Role: lead

NCT07424196Not Yet Recruiting

Physiological Benefits From the Removal of Tracheostomy Tubes (Obtained Via Wearable Devices)

Role: collaborator

NCT07620314Phase 1Recruiting

Safety and Efficacy of KSVCBD Injection in B-cell Non-Hodgkin's Lymphoma Expressing CD19 and/or BCMA

Role: lead

NCT07620275Phase 1Recruiting

Safety and Efficacy of KSVCBD Injection in Multiple Myeloma Expressing CD19 and/or BCMA

Role: lead

NCT06692036Not ApplicableEnrolling By Invitation

Adaptive Blood Purification for the Treatment of Patients With Septic Shock

Role: collaborator

NCT07612618Not Yet Recruiting

Prediction of Age-Related Hearing Loss Based on Comprehensive Risk Factors

Role: lead

NCT07612605Early Phase 1Not Yet Recruiting

Yiqi Huoxue Jiedu Formula Combined With Bacteriophages in the Treatment of Severe Pneumonia

Role: lead

NCT07613411Early Phase 1Not Yet Recruiting

Safety and Efficacy of KSVCBD Injection in Autoimmune Diseases

Role: lead

NCT07198425Not Yet Recruiting

Predicting Success of Decannulation Using Wearable-derived Physiology

Role: collaborator

NCT07608640Not Yet Recruiting

Management of Age-Related Auditory Decline and Early Warning of Its Co-occurring Dementia

Role: lead

NCT07602101Phase 2Not Yet Recruiting

Neoadjuvant PD-L1 Inhibitor Plus Anlotinib for Kidney Preservation in Complex Renal Cell Carcinoma

Role: collaborator

NCT07581626Phase 2Not Yet Recruiting

Short-Course Online Adaptive Radiotherapy Combined With Chemotherapy, Targeted Therapy and Immunotherapy as Total Neoadjuvant Therapy (TNT) for Locally Advanced Rectal Cancer

Role: lead

NCT07592754Early Phase 1Not Yet Recruiting

The Safety and Efficacy of KSVCBD Injection in Neuromyelitis Optica Spectrum Disorder.

Role: lead

NCT07583225Not Yet Recruiting

Prospective Study of High-penetration Super-resolution Transcranial Ultrasound for Early Identification of Postoperative Intracranial Metallic Targets After Aneurysm Clipping

Role: lead

NCT07587762Not ApplicableRecruiting

Predicting the Clinical Advantages of Speaking Valves Through Wearable Devices

Role: collaborator

NCT07585981Recruiting

Early Application of Budesonide Enteric-coated Capsules in the Treatment of Primary IgA Nephropathy.

Role: lead